Piomic Medical

Piomic Medical AG is a Swiss medical device company at the forefront of innovation in the treatment of hard-to-heal wounds. Founded and based in Zurich since 2016, the company has developed the COMS® One Therapy System - a portable, hand-held device that incorporates concurrent optical and magnetic stimulation technologies intended to promote wound healing in chronic leg and foot ulcers.

With approximately 50 million reported cases of patients suffering from hard-to-heal wounds globally, Piomic addresses a significant burden on healthcare systems worldwide. The COMS® One Therapy System is designed to be intuitive and conform to established workflows of wound care professionals, integrating smoothly into the patient's healing journey across all care environments, including hospitals, outpatient facilities, and patients' homes.

The company has achieved key regulatory milestones, including CE Mark approval in 2020 and FDA Breakthrough Device Designation for its COMS® One Therapy System. Piomic is currently conducting the MAVERICKS clinical trial focusing on therapy-refractory diabetic foot ulcers and has recently received Category III CPT codes, marking significant progress in U.S. reimbursement. The company has raised CHF 7.5 million in Series A funding and continues to expand its presence in both European and U.S. markets.